PDCD1 and nonpapillary renal cell carcinoma: The human IgG4 anti-PD-1 monoclonal antibody, Nivolumab, was recently approved to treat advanced (metastatic) clear cell renal cell carcinoma (ccRCC) patients who have received a prior anti-angiogenic therapy [2] resulting in 30% of clinical response.